BPC-157: thirty years of tissue-repair findings, read carefully.

BPC-157 is a synthetic 15-amino-acid sequence — hence its formal designation as a pentadecapeptide — derived from a protein found in human gastric juice. The full name is Body Protection Compound 157; the number refers to the 157th amino acid sequence identified in the Sikiric laboratory's original fractionation work on gastric proteins in the early 1990s. Its molecular weight is 1,419.5 daltons.

The peptide's origin in gastric tissue is not incidental to its properties. Gastric mucosal proteins must withstand an environment of acid and proteolytic enzymes; BPC-157 inherits a structural stability that makes it orally active in rodent models — an unusual property for a peptide of its size. It has been observed to remain intact in human gastric juice for extended periods exceeding 24 hours in stability studies.

The research literature spans from 1993 to the present, concentrated heavily in the Zagreb laboratory of Predrag Sikiric and collaborators. Independent replication of the Sikiric group's core findings is limited — a genuine limitation the literature itself acknowledges — though a 2025 systematic review of 36 studies in the journal HSS Journal confirmed consistent preclinical musculoskeletal outcomes across the body of published work.^[16]

BPC-157 mechanism of action is the primary focus of the mechanistic literature, and it is worth reading in full before forming conclusions about effect sizes or translation potential.

The dominant mechanism identified across the literature is upregulation of VEGFR2 — vascular endothelial growth factor receptor 2 — and activation of the downstream VEGFR2-Akt-eNOS signaling pathway. In a 2017 study using a rat hind-limb ischemia model, Hsieh and colleagues confirmed both in vivo and in vitro that BPC-157 increased VEGFR2 expression, accelerated angiogenesis, and restored limb perfusion faster than untreated controls.^[1]

A second mechanism, characterized by the same group in 2020, involves the Src-Caveolin-1-eNOS pathway: BPC-157 disrupts the inhibitory complex formed between Caveolin-1 and eNOS, freeing eNOS to produce nitric oxide and trigger vasodilation.^[2] These two angiogenic and vasomotor pathways are the most thoroughly characterized molecular targets in the BPC-157 literature.

A third pathway — growth hormone receptor upregulation — was identified by Chang et al. in 2014. In rat Achilles tendon fibroblasts, BPC-157 increased GHR mRNA and protein levels in a dose- and time-dependent manner, and subsequent GH stimulation activated JAK2 signaling and increased fibroblast proliferation.^[3] This suggests BPC-157 may amplify growth hormone's tissue-repair signal locally, rather than raising circulating GH.

Across the broader literature, BPC-157 also modulates prostaglandin and nitric oxide systems to produce cytoprotective effects in liver, kidney, heart, and brain tissue — effects catalogued in a 2020 review covering thirty years of findings from the Sikiric group.^[15]

The research record covers several distinct tissue domains, each with its own body of published studies:

Tendon and ligament. Medial collateral ligament transection in rats treated with BPC-157 showed consistent functional, biomechanical, macroscopic, and histological improvements over 90 days across intraperitoneal, oral, and topical delivery routes at doses of 10 μg/kg and 10 ng/kg.^[4] Achilles tendon detachment models show improved tendon-to-bone healing, better collagen organization, and reversal of corticosteroid-aggravated healing impairment at 10 μg/kg intraperitoneal.^[5]

Muscle. Crush-injury and surgical transection models show full functional restoration and reversal of corticosteroid-impaired healing within 14 days.^[6] Quadriceps myotendinous junction dissection studies show full recovery with no contracture or walking dysfunction.^[14]

Gastrointestinal. BPC-157 has been studied in ulcer, fistula, and inflammatory bowel disease models. In colocutaneous fistula models, parenteral and peroral BPC-157 accelerated closure faster than sulphasalazine or corticosteroid controls, and the effect was maintained even when nitric oxide synthesis was suppressed.^[11]

Neuroprotection. In spinal cord compression models, 10 μg/kg administered 10 minutes post-injury produced full functional recovery sustained over one year, with prevention of demyelination and upregulation of all three NOS isoforms.^[7]

Cardiac and vascular. In rat cardiac injury models, BPC-157 counteracted myocardial infarction, pulmonary hypertension, arrhythmias, and thrombosis through collateral vessel activation.^[9]

A 2021 wound-healing review confirmed BPC-157 efficacy across incisional wounds, deep burns, diabetic ulcers, and alkali burns in rodent models, with no reported lethal dose in any published study.^[12] Explore the gut and gastrointestinal research and human trials and clinical status sections for the most clinically proximate data.

No. BPC-157 is a peptide — a short chain of amino acids — and has no steroidal ring structure. It does not bind androgen, estrogen, or glucocorticoid receptors. The mechanism literature places its primary targets at VEGFR2, eNOS, GHR, and the nitric oxide system, none of which are steroid hormone pathways.^[1][2][3]

No. BPC-157 is a pentadecapeptide — 15 amino acids — not a 191-amino-acid pituitary hormone. One study by Chang et al. (2014) found that BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts via JAK2 signaling, amplifying the response to growth hormone when GH is present.^[3] That is a receptor-sensitizing effect, not a direct elevation of circulating GH. BPC-157 does not stimulate pituitary GH secretion.

Body Protection Compound-157. The designation reflects both function — the observed cytoprotective and tissue-repair properties attributed to the molecule — and provenance: the number identifies it as the 157th amino acid sequence screened from the gastric protein fractionation work in the Sikiric laboratory in Zagreb.

The preclinical record is large and internally consistent: more than thirty rodent studies, multiple tissue types, multiple delivery routes, and reproducible effect sizes across doses ranging from 10 ng/kg to 10 μg/kg. A 2026 review in the International Journal of Molecular Sciences confirmed the mechanistic evidence for tissue repair via angiogenesis, collagen synthesis, fibroblast activity, and nitric oxide pathway modulation.^[17]

The significant gap is human data. Three small pilot studies have been published — an interstitial cystitis intravesicular study (n=12), an intra-articular knee pain case series (n=12, 7/12 reporting sustained relief), and a two-person IV safety pilot — but no large-scale randomized controlled trial has completed and published results.^[16][17][20] The 2026 review explicitly calls for comprehensive evaluation before clinical translation.